Literature DB >> 10516021

Evaluation of novel human immunodeficiency virus type 1 Gag DNA vaccines for protein expression in mammalian cells and induction of immune responses.

J T Qiu1, R Song, M Dettenhofer, C Tian, T August, B K Felber, G N Pavlakis, X F Yu.   

Abstract

Human immunodeficiency virus (HIV)-specific cytotoxic T lymphocytes (CTL) are an important parameter of host defenses that limit viral replication after infection. Induction of effective CTL against conserved viral proteins such as Gag may be essential to the development of a safe and effective HIV type 1 (HIV-1) vaccine. DNA vaccination represents a novel strategy for inducing potent CD8(+) CTL responses in vivo. However, expression of HIV-1 structural proteins by DNA vectors has been hampered by a stringent requirement for coexpression with other viral components, such as Rev and RRE. Furthermore, even with Rev and RRE present, the level of expression of HIV-1 Gag, Pol, or Env is very low in murine cells. These problems have limited our ability to address the key issue of how to generate effective CTL responses to Gag in a mouse model. To overcome this problem, we compared several novel DNA expression vectors for HIV-1 Gag protein expression in primate and mouse cells and for generating immune responses in mice after DNA vaccination. A DNA vector containing wild type HIV-1 gag coding sequences did not induce detectable Gag expression in any of the cells tested. Attempts to increase nuclear export of Gag expression RNA by adding the constitutive transport element yielded only a moderate increase in Gag expression in monkey-derived COS cells and an even lower increase in Gag expression in HeLa cells or several mouse cell lines. In contrast, silent-site mutations in the HIV-1 gag coding sequences significantly increased Gag expression levels in all cells tested. Furthermore, this construct induced both Gag-specific antibody and CTL responses in mice after DNA vaccination. Using this construct, we achieved stable expression of HIV-1 Gag in the mouse cell line p815, which can now be used as a target cell for measuring HIV-1 Gag-specific CTL responses in immunized mice. The DNA vectors described in this study should make it possible to systematically evaluate the approaches for maximizing the induction of CTL responses against HIV-1 Gag in mouse and other animal systems.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10516021      PMCID: PMC112947     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  35 in total

Review 1.  Mechanism of action of regulatory proteins encoded by complex retroviruses.

Authors:  B R Cullen
Journal:  Microbiol Rev       Date:  1992-09

2.  Cross-clade recognition of p55 by cytotoxic T lymphocytes in HIV-1 infection.

Authors:  S McAdam; P Kaleebu; P Krausa; P Goulder; N French; B Collin; T Blanchard; J Whitworth; A McMichael; F Gotch
Journal:  AIDS       Date:  1998-04-16       Impact factor: 4.177

3.  Cross-reactions between the cytotoxic T-lymphocyte responses of human immunodeficiency virus-infected African and European patients.

Authors:  D Durali; J Morvan; F Letourneur; D Schmitt; N Guegan; M Dalod; S Saragosti; D Sicard; J P Levy; E Gomard
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

4.  Complete nucleotide sequence of the AIDS virus, HTLV-III.

Authors:  L Ratner; W Haseltine; R Patarca; K J Livak; B Starcich; S F Josephs; E R Doran; J A Rafalski; E A Whitehorn; K Baumeister
Journal:  Nature       Date:  1985 Jan 24-30       Impact factor: 49.962

5.  rev protein of human immunodeficiency virus type 1 affects the stability and transport of the viral mRNA.

Authors:  B K Felber; M Hadzopoulou-Cladaras; C Cladaras; T Copeland; G N Pavlakis
Journal:  Proc Natl Acad Sci U S A       Date:  1989-03       Impact factor: 11.205

6.  Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA.

Authors:  G S Ogg; X Jin; S Bonhoeffer; P R Dunbar; M A Nowak; S Monard; J P Segal; Y Cao; S L Rowland-Jones; V Cerundolo; A Hurley; M Markowitz; D D Ho; D F Nixon; A J McMichael
Journal:  Science       Date:  1998-03-27       Impact factor: 47.728

7.  Serological evidence for virus related to simian T-lymphotropic retrovirus III in residents of west Africa.

Authors:  F Barin; S M'Boup; F Denis; P Kanki; J S Allan; T H Lee; M Essex
Journal:  Lancet       Date:  1985 Dec 21-28       Impact factor: 79.321

8.  A bipartite membrane-binding signal in the human immunodeficiency virus type 1 matrix protein is required for the proteolytic processing of Gag precursors in a cell type-dependent manner.

Authors:  Y M Lee; C J Tian; X F Yu
Journal:  J Virol       Date:  1998-11       Impact factor: 5.103

9.  A human cell factor is essential for HIV-1 Rev action.

Authors:  D Trono; D Baltimore
Journal:  EMBO J       Date:  1990-12       Impact factor: 11.598

10.  Defective presentation to class I-restricted cytotoxic T lymphocytes in vaccinia-infected cells is overcome by enhanced degradation of antigen.

Authors:  A Townsend; J Bastin; K Gould; G Brownlee; M Andrew; B Coupar; D Boyle; S Chan; G Smith
Journal:  J Exp Med       Date:  1988-10-01       Impact factor: 14.307

View more
  31 in total

1.  Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by HIV-1-based lentivirus vectors expressing transdominant Rev.

Authors:  M R Mautino; N Keiser; R A Morgan
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

2.  Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization.

Authors:  Bimal K Chakrabarti; Wing-pui Kong; Bei-yue Wu; Zhi-Yong Yang; Jacques Friborg; Xu Ling; Steven R King; David C Montefiori; Gary J Nabel
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

3.  Soluble multi-trimeric TNF superfamily ligand adjuvants enhance immune responses to a HIV-1 Gag DNA vaccine.

Authors:  Saravana K Kanagavelu; Victoria Snarsky; James M Termini; Sachin Gupta; Suzanne Barzee; Jacqueline A Wright; Wasif N Khan; Richard S Kornbluth; Geoffrey W Stone
Journal:  Vaccine       Date:  2011-12-04       Impact factor: 3.641

4.  DNA vaccines expressing different forms of simian immunodeficiency virus antigens decrease viremia upon SIVmac251 challenge.

Authors:  Margherita Rosati; Agneta von Gegerfelt; Patricia Roth; Candido Alicea; Antonio Valentin; Marjorie Robert-Guroff; David Venzon; David C Montefiori; Phil Markham; Barbara K Felber; George N Pavlakis
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

5.  Alphavirus replicon approach to promoterless analysis of IRES elements.

Authors:  K I Kamrud; M Custer; J M Dudek; G Owens; K D Alterson; J S Lee; J L Groebner; J F Smith
Journal:  Virology       Date:  2006-12-06       Impact factor: 3.616

6.  Effects of MIP-1 alpha, MIP-3 alpha, and MIP-3 beta on the induction of HIV Gag-specific immune response with DNA vaccines.

Authors:  Ruijiang Song; Shuqin Liu; Kam W Leong
Journal:  Mol Ther       Date:  2007-03-13       Impact factor: 11.454

7.  Recombinant adeno-associated virus vectors induce functionally impaired transgene product-specific CD8+ T cells in mice.

Authors:  Shih-Wen Lin; Scott E Hensley; Nia Tatsis; Marcio O Lasaro; Hildegund C J Ertl
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

8.  Enhanced mucosal immunoglobulin A response of intranasal adenoviral vector human immunodeficiency virus vaccine and localization in the central nervous system.

Authors:  Franck Lemiale; Wing-pui Kong; Levent M Akyürek; Xu Ling; Yue Huang; Bimal K Chakrabarti; Michael Eckhaus; Gary J Nabel
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

9.  Enhancing efficacy of HIV gag DNA vaccine by local delivery of GM-CSF in murine and macaque models.

Authors:  Ruijiang Song; Shuqin Liu; Robert J Adams; Kam W Leong
Journal:  J Interferon Cytokine Res       Date:  2006-06       Impact factor: 2.607

10.  Multiple effects of codon usage optimization on expression and immunogenicity of DNA candidate vaccines encoding the human immunodeficiency virus type 1 Gag protein.

Authors:  L Deml; A Bojak; S Steck; M Graf; J Wild; R Schirmbeck; H Wolf; R Wagner
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.